Protalix BioTherapeutics, Inc. Common Stock PLX
i
Market dataready · fetched 2026-11-12T00:44:55.904Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-02-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:30:00.006805974Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T00:44:54.699166+00:00
Protalix BioTherapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.69 | 63.8% | 54.3% | |||
| 25Δ | 4.50 | 64.0% | 50.3% | 2.78 | 74.6% | 23.2% |
| 30Δ | 4.32 | 64.2% | 46.2% | 3.06 | 81.1% | 21.5% |
| 35Δ | 4.14 | 64.4% | 42.2% | 3.34 | 87.5% | 19.8% |
| 40Δ | 3.96 | 64.7% | 38.1% | 3.63 | 94.0% | 18.1% |
| 45Δ | 3.78 | 64.9% | 34.0% | 3.91 | 100.5% | 16.4% |
| 50Δ | 3.60 | 65.1% | 30.0% | 4.19 | 107.0% | 14.7% |
| 55Δ | 3.42 | 65.3% | 25.9% | 4.47 | 113.5% | 12.9% |
| 60Δ | 3.24 | 65.5% | 21.9% | 4.76 | 120.0% | 11.2% |
| 65Δ | 3.05 | 65.8% | 17.8% | 5.23 | 129.1% | 9.5% |
| 70Δ | 2.87 | 66.0% | 13.8% | 6.91 | 154.9% | 7.9% |
| 75Δ | 2.69 | 66.2% | 9.7% | |||
| 80Δ | 2.51 | 66.4% | 5.7% | |||
20Δ
- Pseudo strike
- 4.69
- IV
- 63.8%
- B/E move
- 54.3%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.50
- IV
- 64.0%
- B/E move
- 50.3%
- Pseudo strike
- 2.78
- IV
- 74.6%
- B/E move
- 23.2%
30Δ
- Pseudo strike
- 4.32
- IV
- 64.2%
- B/E move
- 46.2%
- Pseudo strike
- 3.06
- IV
- 81.1%
- B/E move
- 21.5%
35Δ
- Pseudo strike
- 4.14
- IV
- 64.4%
- B/E move
- 42.2%
- Pseudo strike
- 3.34
- IV
- 87.5%
- B/E move
- 19.8%
40Δ
- Pseudo strike
- 3.96
- IV
- 64.7%
- B/E move
- 38.1%
- Pseudo strike
- 3.63
- IV
- 94.0%
- B/E move
- 18.1%
45Δ
- Pseudo strike
- 3.78
- IV
- 64.9%
- B/E move
- 34.0%
- Pseudo strike
- 3.91
- IV
- 100.5%
- B/E move
- 16.4%
50Δ
- Pseudo strike
- 3.60
- IV
- 65.1%
- B/E move
- 30.0%
- Pseudo strike
- 4.19
- IV
- 107.0%
- B/E move
- 14.7%
55Δ
- Pseudo strike
- 3.42
- IV
- 65.3%
- B/E move
- 25.9%
- Pseudo strike
- 4.47
- IV
- 113.5%
- B/E move
- 12.9%
60Δ
- Pseudo strike
- 3.24
- IV
- 65.5%
- B/E move
- 21.9%
- Pseudo strike
- 4.76
- IV
- 120.0%
- B/E move
- 11.2%
65Δ
- Pseudo strike
- 3.05
- IV
- 65.8%
- B/E move
- 17.8%
- Pseudo strike
- 5.23
- IV
- 129.1%
- B/E move
- 9.5%
70Δ
- Pseudo strike
- 2.87
- IV
- 66.0%
- B/E move
- 13.8%
- Pseudo strike
- 6.91
- IV
- 154.9%
- B/E move
- 7.9%
75Δ
- Pseudo strike
- 2.69
- IV
- 66.2%
- B/E move
- 9.7%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.51
- IV
- 66.4%
- B/E move
- 5.7%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The…
More →PRLD
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key…
More →PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →PROK
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.
More →PRQR
Description unavailable
More →PRTA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The…
More →